John R Mascola
Overview
Explore the profile of John R Mascola including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
543
Citations
46691
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Dias J, Fabozzi G, Fourati S, Chen X, Liu C, Ambrozak D, et al.
Nat Commun
. 2024 Aug;
15(1):7461.
PMID: 39198422
Anti-HIV-1 broadly neutralizing antibodies (bNAbs) have the dual potential of mediating virus neutralization and antiviral effector functions through their Fab and Fc domains, respectively. So far, bNAbs with enhanced Fc...
12.
Moysi E, Sharma A, ODell S, Georgakis S, Del Rio Estrada P, Torres-Ruiz F, et al.
bioRxiv
. 2024 Aug;
PMID: 39131331
A subset of people living with HIV (PLWH) can produce broadly neutralizing antibodies (bNAbs) against HIV, but the lymph node (LN) dynamics that promote the generation of these antibodies are...
13.
Zhang P, Gorman J, Tsybovsky Y, Lu M, Liu Q, Gopan V, et al.
Cell Rep
. 2024 Jul;
43(8):114518.
PMID: 39028623
Soluble HIV-1 envelope (Env) trimers may serve as effective vaccine immunogens. The widely utilized SOSIP trimers have been paramount for structural studies, but the disulfide bond they feature between gp120...
14.
Galvez N, Cao Y, Nitido A, Deal C, Boutros C, MacDonald S, et al.
bioRxiv
. 2024 Jul;
PMID: 39026699
Broadly neutralizing antibodies (bNAbs) have shown great promise for prevention and treatment of HIV infection. Breadth of bNAb neutralization, measured across panels of diverse viral isolates, is often used as...
15.
Walsh S, Gay C, Karuna S, Hyrien O, Skalland T, Mayer K, et al.
PLoS Med
. 2024 Jun;
21(6):e1004329.
PMID: 38913710
Background: Broadly neutralizing antibodies (bnAbs) are a promising approach for HIV-1 prevention. In the Antibody Mediated Prevention (AMP) trials, a CD4-binding site targeting bnAb, VRC01, administered intravenously (IV), demonstrated 75%...
16.
Roark R, Habib R, Gorman J, Li H, Connell A, Bonsignori M, et al.
bioRxiv
. 2024 Jun;
PMID: 38903070
Highlights: Isolated 11 V2 apex-targeted HIV-neutralizing lineages from 10 SHIV-infected Indian-origin rhesus macaquesCryo-EM structures of Fab-Env complexes for nine rhesus lineages reveal modes of recognition that mimic three modes of...
17.
Zhang B, Chuang G, Biju A, Biner D, Cheng J, Wang Y, et al.
Cell Rep
. 2024 May;
43(6):114285.
PMID: 38819987
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a plasma protein that controls cholesterol homeostasis. Here, we design a human PCSK9 mimic, named HIT01, with no consecutive 9-residue stretch in common...
18.
Ober Shepherd B, Scott P, Hutter J, Lee C, McCauley M, Guzman I, et al.
Lancet Microbe
. 2024 May;
5(6):e581-e593.
PMID: 38761816
Background: A self-assembling SARS-CoV-2 WA-1 recombinant spike ferritin nanoparticle (SpFN) vaccine co-formulated with Army Liposomal Formulation (ALFQ) adjuvant containing monophosphoryl lipid A and QS-21 (SpFN/ALFQ) has shown protective efficacy in...
19.
Cottrell C, Hu X, Lee J, Skog P, Luo S, Flynn C, et al.
Sci Transl Med
. 2024 May;
16(748):eadn0223.
PMID: 38753806
A protective HIV vaccine will likely need to induce broadly neutralizing antibodies (bnAbs). Vaccination with the germline-targeting immunogen eOD-GT8 60mer adjuvanted with AS01 was found to induce VRC01-class bnAb precursors...
20.
Awan S, Pegu A, Strom L, Carter C, Hendel C, Holman L, et al.
JCI Insight
. 2024 Apr;
9(7).
PMID: 38587079
BACKGROUNDBroadly neutralizing monoclonal antibodies (bNAbs) represent a promising strategy for HIV-1 immunoprophylaxis and treatment. 10E8VLS and VRC07-523LS are bNAbs that target the highly conserved membrane-proximal external region (MPER) and the...